SCHEMBL7534719

SCHEMBL7534719

[CH2]CCN(C(N)=O)c1ccc(Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
OGG1 O15527 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5682214 0.83 HTT (0.49) SMN1; SMN2MEN1KMT2ATP53TSHR
SCHEMBL5681948 0.81 ALOX5 (0.42) ALOX5SMN1; SMN2OGG1MEN1KMT2A
SCHEMBL7534269 0.80 TSHR (0.46) ALOX5SMN1; SMN2TP53TSHR
SCHEMBL27544700 0.79 ALDH1A1 (0.46) ALOX5SMN1; SMN2OGG1MEN1KMT2A
SCHEMBL7539909 0.78 KMT2A (0.47) SMN1; SMN2MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL6111921 0.74 ALOX5 (0.39) ALOX5SMN1; SMN2OGG1MEN1KMT2A
SCHEMBL6037579 0.73 ADRA2C (0.50) SMN1; SMN2MEN1KMT2ATP53TSHR
SCHEMBL16488346 0.73 HPGD (0.39) ALOX5SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL7220192 0.71 ADRA2C (0.49) SMN1; SMN2MEN1KMT2ATP53TSHR
SCHEMBL16488327 0.71 ALOX5 (0.44) ALOX5SMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1200395-A1 UREA DERIVATIVES AS INHIBITORS OF CCR-3 RECEPTOR KIRIN BEER KABUSHIKI KAISHA (JP) 2002-05-02 EP claimed
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
WO-2001009088-A1 UREA DERIVATIVES AS INHIBITORS OF CCR-3 RECEPTOR KIRIN BEER KABUSHIKI KAISHA (JP) 2001-02-08 WO claimed
EP-1200395-A1 UREA DERIVATIVES AS INHIBITORS OF CCR-3 RECEPTOR KIRIN BEER KABUSHIKI KAISHA (JP) 2002-05-02 EP disclosed
WO-2001009088-A1 UREA DERIVATIVES AS INHIBITORS OF CCR-3 RECEPTOR KIRIN BEER KABUSHIKI KAISHA (JP) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 ALOX5 1041/4885SMN1; SMN2 4446/4885OGG1 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.